STOCK TITAN
  1. Home
  2. News
  3. AVIR

Atea Pharmaceuticals Inc - AVIR STOCK NEWS

IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
conferences earnings
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
clinical trial covid-19
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
clinical trial
Stock AVIR logo
Atea Pharmaceuticals Inc

Nasdaq:AVIR

AVIR Rankings

#4159 Ranked by Market Cap
#4631 Ranked by Stock Gains
N/A Ranked by Dividends

AVIR Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About AVIR

atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.